Ostatné · IBRX
ImmunityBio, Inc.
Fundamenty firmy Healthcare · Biotechnology · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 3 hodnotení
silný nákup
- Najnižší cieľ
- 12,00
- Priemerný cieľ
- 13,00
- Najvyšší cieľ
- 15,00
- Potenciál
- +27,5 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | -0,05 | -0,09–0,00 | -0,07 | +28,6 % |
| budúci štvrťrok | -0,04 | -0,09–0,00 | -0,06 | +27,8 % |
| tento rok | -0,92 | -0,93–-0,90 | -0,38 | −140,8 % |
| budúci rok | -0,14 | -0,35–0,07 | -0,92 | +84,7 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 59,2 mil. | 32,1 mil. | +84,7 % |
| budúci štvrťrok | 71,2 mil. | 38,3 mil. | +86,0 % |
| tento rok | 225,7 mil. | 113,3 mil. | +99,3 % |
| budúci rok | 454,4 mil. | 225,7 mil. | +101,3 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Cohen Cheryl LDirector | predaj | 1,2 mil. | 02.07. |
| Cohen Cheryl LDirector | uplatnenie opcií | 166 817 | 02.07. |
| Selecky Christobel E.Director | predaj | 1,4 mil. | 01.07. |
| Selecky Christobel E.Director | uplatnenie opcií | 476 489 | 01.07. |
| Selecky Christobel E.Director | predaj | 871 216 | 30.06. |
| Selecky Christobel E.Director | uplatnenie opcií | 284 370 | 30.06. |
| Simon Barry J. M.d.Director | predaj | 196 908 | 24.06. |
| Simon Barry J. M.d.Director | predaj | 165 306 | 04.06. |
| Soon-Shiong PatrickOfficer, Director and Beneficial Owner | uplatnenie opcií | 25,0 mil. | 31.03. |
| Simon Barry J. M.d.Director | predaj | 900 788 | 24.02. |
| Simon Barry J. M.d.Director | predaj | 1,8 mil. | 23.02. |
| Selecky Christobel E.Director | predaj | 250 000 | 23.02. |
Kto vlastní akcie
Blackrock Inc.3,22 %
State Street Corporation2,02 %
Vanguard Portfolio Management LLC1,69 %
Vanguard Capital Management LLC1,48 %
Shaw D.E. & Co., Inc.1,09 %
Two Sigma Investments, LP1,05 %
Geode Capital Management, LLC0,93 %
Millennium Management Llc0,53 %
O firme (popis z Yahoo Finance, anglicky)
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
Technické signály
- Rastový trend – Kurz nad SMA50 aj SMA200, SMA50 nad SMA200
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou IBRX.